Income Statement
OLEMA PHARMACEUTICALS, INC.
OLMA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
178.70 | 142.26 | 104.96 | 106.99 | 71.49 |
|
Research & Development
|
157.70 | 124.52 | 86.14 | 82.27 | 51.10 |
|
Selling, General & Administrative
|
21.00 | 17.74 | 18.82 | 24.71 | 20.39 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-178.70 | -142.26 | -104.96 | -106.99 | -71.49 |
|
Non-Operating Income
|
16.25 | 12.78 | 8.31 | 2.20 | 0.40 |
|
Interest Income
|
16.22 | 12.68 | 8.33 | 2.23 | 0.44 |
|
Interest Expense
|
0.10 | - | - | - | - |
|
Other Non-Op Income / Expense
|
0.02 | 0.10 | -0.02 | -0.03 | -0.05 |
|
Income Before Tax
|
-162.45 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-162.45 | -129.47 | -96.66 | -104.79 | -71.10 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-178.21 | -141.87 | -104.58 | -106.63 | -71.33 |
|
Earnings Per Share (Basic)
|
-1.87 | -2.20 | -2.14 | -2.62 | -1.80 |
|
Diluted EPS
|
-1.87 | -2.20 | -2.14 | -2.62 | -1.80 |
|
Weighted Average Shares
|
87.01 | 58.74 | 45.25 | 40.00 | 39.52 |
|
Diluted Weighted Avg Shares
|
87.01 | 58.74 | 45.25 | 40.00 | 39.52 |
|
Comprehensive Income
|
-161.97 | -129.68 | -94.50 | -106.45 | -71.25 |